Brief: Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss As A Monotherapy, Enhancement Of GLP-1RA Therapy In Combination, And Effective Maintenance Following Discontinuation Of GLP-1RA Therapy
12/08/2025 13:11
Aug 12 (Reuters) - Aardvark Therapeutics Inc AARD.O: AARDVARK THERAPEUTICS ANNOUNCES ARD-201 PRECLINICAL OBESITY DATA SHOWING SIGNIFICANT WEIGHT LOSS AS A MONOTHERAPY, ENHANCEMENT OF GLP-1RA THERAPY IN COMBINATION, AND EFFECTIVE MAINTENANCE FOLLOWING DISCONTINUATION OF GLP-1RA THERAPY AARDVARK THERAPEUTICS INC - ARD-201 ACHIEVES 19% BODY WEIGHT REDUCTION IN 30 DAYS AARDVARK THERAPEUTICS INC - ARD-201 REDUCES WEIGHT REGAIN AFTER TIRZEPATIDE DISCONTINUATION AARDVARK THERAPEUTICS INC - PHASE 2 STRENGTH TRIAL TO START IN 1H 2026 FOR WEIGHT LOSS Source text: ID:nGNX2KNlNq Further company coverage: AARD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aardvark Therapeutics
See all newsBrief: Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., Mba, To Its Board Of Directors
Aardvark Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction
Aardvark Therapeutics, Inc. expected to post a loss of 87 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Intel, Nvidia, Aardvark